Economic Burden of COPD in the Presence of Comorbidities.
about
Global burden of COPDObstructive and Restrictive Lung Function Measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and RecommendationsImpact of Comorbidities Among Medicaid Enrollees With Chronic Obstructive Pulmonary Disease, United States, 2009Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France.Analysis of pulmonary function test results in a health check-up population.Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS).The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life.Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease.Hydrogen sulfide inhibits transforming growth factor beta-1 induced bronchial epithelial-mesenchymal transition.Relationship of airflow limitation severity with work productivity reduction and sick leave in a Japanese working populationStudy of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease.Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy.The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease.Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis.Positive Airway Pressure Therapies and Hospitalization in Chronic Obstructive Pulmonary Disease.Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease.Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.Australian and New Zealand Pulmonary Rehabilitation Guidelines.Senior high-cost healthcare users' resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada.The annual direct costs of stable COPD in Greece.Incidence and risk of chronic obstructive pulmonary disease in a Korean community-based cohort.Early Endotyping - A Chance for Intervention in COPD.Clinical significance of nuclear factor erythroid 2-related factor 2 in patients with chronic obstructive pulmonary disease.Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients
P2860
Q26780363-36446F72-543F-4046-A816-D12EE68A0C13Q28387680-75961C8D-4587-452E-9A93-9656BC9FEF03Q30245662-2498C04C-898D-4D53-8639-FF57AE021830Q33567206-67A72820-C82F-4ACB-9430-29BEB773B819Q36057662-AEEAC3E1-D4D4-48C8-AA9A-7C6503685EEEQ36138289-8D768DAC-06D5-4C67-9AA6-147BF63148EDQ36433264-06D6DCA8-0435-4C99-A9A8-5B95765F960EQ36646206-1F2E3020-36F9-4902-A0F5-2D62BAA22165Q36692766-972DF76C-B361-4C79-8D81-7AFD21211D45Q36694652-178BF3E8-6C7D-462A-8E78-7AC55BB5A947Q36710280-3219A6FF-1B71-4E36-92A6-F16305248FE9Q36732324-080D50E9-AFB3-43B8-82DF-FBA3DB03C2FAQ36945570-87F5942C-C438-4551-B5D0-9E225767B2FCQ37623969-4B2B5DB9-A37D-48FE-97BE-B78ADE0F7DCEQ38513898-608C369C-EBC1-430A-AFF1-93FF60D391EAQ38794102-111F1D2B-EAB8-452F-AF31-8264E5B14BFDQ39019476-9742821C-5CA0-4A41-B575-1E01B6E144E7Q40557048-3F6A4411-C696-4338-BE68-44F5199AA056Q42280547-2DFADEE1-4634-435B-A610-D0C389FD11F2Q47128813-6A30D6CF-A1E8-4765-B1E1-DF1AF6ACEDF2Q47568762-2037B0E9-1F2F-447B-A76D-375F53C8F4FEQ48528389-D4BE13F0-9973-4D73-BB91-C6C5E61E1158Q49337347-1D2E63FE-A51C-433B-A8AD-0341E78E205BQ49963482-BA933C6B-8F35-4F84-8469-1141D18D5880Q52664517-3CAE4637-9CA7-43D5-8326-89AC2D51001DQ55518486-B9C07E77-2A51-49B8-8F41-5DEA41014819Q58756370-CC3CB11C-5A3A-4CD2-A474-2A9420AF3724
P2860
Economic Burden of COPD in the Presence of Comorbidities.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Economic Burden of COPD in the Presence of Comorbidities.
@ast
Economic Burden of COPD in the Presence of Comorbidities.
@en
type
label
Economic Burden of COPD in the Presence of Comorbidities.
@ast
Economic Burden of COPD in the Presence of Comorbidities.
@en
prefLabel
Economic Burden of COPD in the Presence of Comorbidities.
@ast
Economic Burden of COPD in the Presence of Comorbidities.
@en
P2093
P2860
P356
P1433
P1476
Economic Burden of COPD in the Presence of Comorbidities
@en
P2093
Haijun Tian
Huanxue Zhou
Keiko Higuchi
Tzy-Chyi Yu
Yangyang Li
P2860
P304
P356
10.1378/CHEST.14-2434
P407
P577
2015-07-01T00:00:00Z